KRTX News and Press, Karuna Therapeutics Inc. From 11/07/19

Phase 2 clinical trial of KarXT for the treatment of acute psychosis in patients with schizophrenia remains on track with topline data expected in late 2019 Phase 1b clinical trials for the treatment of psychosis in Alzheimer’s disease and pain on track to commence by the ...

Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company primarily focused on developing novel therapies to address disabling neuropsychiatric conditions, today announced that members of its senior management team are scheduled to participate in two upcoming invest...

The following slide deck was published by Karuna Therapeutics, Inc. in conjunction with this Read more ...

Karuna Therapeutics (NASDAQ: KRTX ): Q2 GAAP EPS of -$146.00. More news on: Karuna Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Completed multiple financings in 2019, including initial public offering, raising $184.7 million to fund clinical development of novel CNS pipeline Results from Phase 2 clinical trial of KarXT for the treatment of acute psychosis in patients with schizophrenia remains on track t...

Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company primarily focused on developing novel therapies to address disabling neuropsychiatric conditions, today announced that Andrew Miller, Ph.D., founder and chief operating officer at Karuna, will present at the ...